SavedAdd your journal

Journals / Turkish Journal of Rheumatology(.)Archives of Rheumatology / 2011 / Cilt: 26 - Sayı: 2

Adalimumab Tedavisine İyi Yanıt Veren Bir Ailesel Akdeniz Ateşi Olgusu

A Case with Familial Mediterranean Fever which Responds Well to Adalimumab Treatment

Özgür ORTANCIL
Aslan SANLI
Perihan SAPMAZ BULMUŞ
Selda SARIKAYA
Pages
158–162
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We conclude that TNF-? blockers may be a therapeutic option when conventional treatment is ineffective in patients with FMF.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ankylosing spondylitis (AS) may accompany Familial Mediterranean fever (FMF).
📊
Key Findings & Data:In this article, we present a 48-year-old male FMF case with accompanying AS who was successfully treated with a tumor necrosis factor- alpha (TNF-?) inhibitor (adalimumab).
💡
Conclusion & Impact:We conclude that TNF-? blockers may be a therapeutic option when conventional treatment is ineffective in patients with FMF.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Ankylosing spondylitis (AS) may accompany Familial Mediterranean fever (FMF). In this article, we present a 48-year-old male FMF case with accompanying AS who was successfully treated with a tumor necrosis factor- alpha (TNF-?) inhibitor (adalimumab). Colchicine and other disease modifying antirheumatic drug (sulfasalazine and leflunomide) treatments had been given before the initiation of the TNF-? inhibitor, but FMF attacks could not be adequately controlled by these treatments. When adalimumab was coadministered with colchicine, the disease activity of AS was improved and the frequency and the severity of the FMF attacks were reduced during the one-year follow-up. We conclude that TNF-? blockers may be a therapeutic option when conventional treatment is ineffective in patients with FMF.

Özet

Ankilozan spondilit (AS) ailesel Akdeniz ateşi (AAA)'ne eşlik edebilir. Bu yazıda eşlik eden AS'si olan ve tümör nekroz faktör alfa (TNF-?) inhibitörü (adalimumab) tedavisiyle başarılı şekilde tedavi edilen 48 yaşında bir erkek AAA olgusu sunuldu. Hastaya TNF-? inhibitörü başlanmadan önce kolşisin ve hastalık modifiye edici ilaç (sulfasalazin ve leflunomid) tedavileri uygulandı fakat bu tedavilerle AAA atakları yeterli derecede kontrol altına alınamadı. Kolşisin tedavisiyle birlikte adalimumab uygulandığında, bir yıllık takip esnasında AS hastalık aktivitesinde düzelme sağlandı ve AAA ataklarının sıklığı ve şiddeti azaldı. Geleneksel tedavilerin etkisiz kaldığı AAA hastalarında TNF-? inhibitörlerinin bir tedavi seçeneği olabileceği düşüncesindeyiz.

🔖

Cite This Article

ORTANCIL, Ö., SANLI, A., BULMUŞ, P. S., SARIKAYA, S. (2011). Adalimumab Tedavisine İyi Yanıt Veren Bir Ailesel Akdeniz Ateşi Olgusu. Turkish Journal of Rheumatology(.)Archives of Rheumatology, Cilt: 26 - Sayı: 2, 158–162. https://ajindex.com/articles/375986

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ozen S. New interest in an old disease: familial Mediterranean fever. Clin Exp Rheumatol 1999;17:745-9.
  2. Nir-Paz R, Ben-Chetrit E, Pikarsky E, Hassin D, Hasin Y, Chajek-Shaul T. Unusual presentation of familial Mediterranean fever: role of genetic diagnosis. Ann Rheum Dis 2000;59:836-8.
  3. Majeed HA, Al-Qudah AK, Qubain H, Shahin HM. The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum 2000;30:138-43.
  4. Ozgocmen S, Ozçakar L, Ardicoglu O, Kocakoc E, Kaya A, Kiris A. Familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol 2006;25:83-7.
  5. Langevitz P, Livneh A, Zemer D, Shemer J, Pras M. Seronegative spondyloarthropathy in familial Mediterranean fever. Semin Arthritis Rheum 1997;27:67-72.
  6. Altındağ Ö, Karakoç M, Soran N. Ankylosing spondylitis together with familial mediterranean fever: a concomitant disease or a feature of FMF? Rheumatism 2007;22:110-3.
  7. Bahadır C, Ocak F, Önal B, Öztürk B, Korkmaz Ö, Önder CB. Familial Mediterranean fever complicated by avasculer necrosis of the femoral head, spondiloarthropathy and osteoporosis: case report Rheumatism 2007;22:36-9.
  8. Knockaert DC, Malysse IG, Peetermans WE. Ankylosing spondylitis. An unusual manifestation of familial Mediterranean fever. Report of a case complicated by amyloidosis and polyneuropathy. Clin Rheumatol 1989;8:408-12.
  9. Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A. Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol 2007;13:38-40.
  10. Nakamura A, Matsuda M, Tazawa K, Shimojima Y, Ikeda S. Successful treatment with infliximab and low- dose methotrexate in a Japanese patient with familial Mediterranean fever. Intern Med 2007;46:1247-9.
  11. Aldea A, Campistol JM, Arostegui JI, Rius J, Maso M, Vives J, et al. A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV- associated periodic inflammatory disorder? Am J Med Genet A 2004;124A:67-73.
  12. Daysal S, Akcil G, Goker B, Haznedaroglu S, Ercan N, Ozturk MA. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum 2005;53:146-7.
  13. Özdolap S, Sarıkaya S, Aktunç E. Familial Mediterranean fever associated with ankylosing spondylitis: a case report. Rheumatism 2006;21:31-3. Kaushik P, el-Sobkie NI, Shehab D, Malaviya AN. Fa